Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2011 (2011), Article ID 515047, 4 pages
Research Article

Arginase Inhibitor in the Pharmacological Correction of Endothelial Dysfunction

1Department of Pharmacology and Pharmaceutical Sciences, Belgorod State University, 85 Pobeda Street, Belgorod 308015, Russia
2Research Institute of Ecological Medicine, Kursk State Medical University, 3 Karl Marx Street, Kursk 305041, Russia
3Department of Pharmacology, Kursk State Medical University, 3 Karl Marx Street, Kursk 305041, Russia

Received 15 February 2011; Accepted 25 April 2011

Academic Editor: Zafar Israili

Copyright © 2011 Mihail V. Pokrovskiy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. S. Sainani and V. G. Maru, “Role of endothelial cell dysfunction in essential hypertension,” Journal of Association of Physicians of India, vol. 52, pp. 966–969, 2004. View at Google Scholar
  2. A. L. Miller, “The effects of a sustained-release L-arginine formulation on blood pressure and vascular compliance in 29 healthy individuals,” Alternative Medicine Review, vol. 11, no. 1, pp. 23–29, 2006. View at Google Scholar
  3. B. J. Hunt and K. M. Jurd, “Endothelial cell activation,” British Medical Journal, vol. 316, no. 7141, pp. 1328–1329, 1998. View at Google Scholar
  4. H. Tomimoto, I. Akiguchi, H. Wakita, A. Osaki, M. Hayashi, and Y. Yamamoto, “Coagulation activation in patients with Binswanger disease,” Archives of Neurology, vol. 56, no. 9, pp. 1104–1108, 1999. View at Publisher · View at Google Scholar
  5. Z. Szolnoki, “Chemical events behind medical chemistry offers new insight into a specific microcirculation disturbance in the brain (a chemical approach to a frequent cerebral phenotype,” Current Medicinal Chemistry, vol. 14, no. 9, pp. 1027–1036, 2007. View at Publisher · View at Google Scholar
  6. Z. Szolnoki, “Pathomechanism of leukoaraiosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis),” NeuroMolecular Medicine, vol. 9, no. 1, pp. 21–34, 2007. View at Publisher · View at Google Scholar
  7. M. Kelm, “The L-arginine-nitric oxide pathway in hypertension,” Current Hypertension Reports, vol. 5, no. 1, pp. 80–86, 2003. View at Google Scholar
  8. N. N. Huynh, E. E. Harris, J. F. P. Chin-Dusting, and K. L. Andrews, “The vascular effects of different arginase inhibitors in rat i/ated aorta and mesenteric arteries,” British Journal of Pharmacology, vol. 156, no. 1, pp. 84–93, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. X. F. Ming, A. G. Rajapakse, J. M. Carvas, J. Ruffieux, and Z. Yang, “Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline,” BMC Cardiovascular Disorders, vol. 9, article 12, 2009. View at Publisher · View at Google Scholar · View at PubMed
  10. M. V. Pokrovskil, T. G. Pokrovskaya, V. I. Kochkarov, and E. B. Artyushkova, “Endothelioprotective properties of L-arginine on a nitric oxide deficiency model,” The Experimental and Clinical Pharmacology, vol. 71, no. 2, pp. 29–31, 2008. View at Google Scholar
  11. M. V. Pokrovskii, V. I. Kochkarov, T. G. Pokrovskaya et al., “Comparative study of potential endothelioprotectors and impaza in modeled nitric oxide defi ciency,” Bulletin of Experimental Biology and Medicine, vol. 148, no. 3, pp. 514–517, 2009. View at Publisher · View at Google Scholar
  12. M. V. Pokrovskiy, T. G. Pokrovskaya, and V.I. Pokrovskaya, The patent. 2301015 Russian Federation, MPK7 A61B 5/02.—no. 2005113243/14.